New NCCN Guidelines for Pediatric Cancers: Advancements in the Management of Pediatric Acute Lymphoblastic Leukemia

January 22, 2021

Advances in approaches to risk stratification which guide tailored interventions have led to significant improvements in clinical outcomes for pediatric acute lymphoblastic leukemia (ALL). However, many patients relapse and experience multiple relapses. One clinical strategy has been to use novel immunotherapies (alone or combined with chemotherapy) in pediatric ALL, which is associated with unique toxicities, and precipitates the need for guidelines regarding effective supportive care to achieve optimal clinical outcomes. Another strategy is aimed at enhancing our understanding of the underlying biology of relapse, and determining ways to modify therapy based on a patient’s genetic and pharmacogenomic factors. The NCCN Guidelines for pediatric ALL will help inform clinicians about these approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage pediatric patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize current treatment strategies for pediatric ALL
  • Outline novel and emerging molecular targeted therapy and immunotherapy for pediatric ALL management
  • Discuss impact of pharmacogenomics and therapeutic drug monitoring in optimizing therapy for pediatric ALL
Additional information
Supporters: 

This activity is supported by educational funding provided by Amgen.

This activity is supported by educational grants from:

  • Novartis
  • Seagen Inc. (formerly Seattle Genetics, Inc.)
Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
11/09/2020
Course expires: 
04/04/2021
Event starts: 
01/22/2021 - 2:00pm EST
Event ends: 
01/22/2021 - 3:00pm EST
Cost:
$0.00
Part of: 
New NCCN Guidelines for Pediatric Cancers: A Webinar Series
Add to calendar: 

Hiroto Inaba, MD, PhD
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

Cyrine-Eliana Haidar, PharmD, BCPS, BCOP
St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

 

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Faculty Disclosures
The faculty listed below discloses no relevant financial relationships: 
Cyrine-Eliana Haidar, PharmD, BCPS, BCOP

The faculty listed below discloses the following relevant financial relationships: 
Hiroto Inaba, MD, PhD 
Amgen Inc.: Grant/Research Support
Incyte Corporation: Grant/Research Support
Jazz Pharmaceuticals Inc.: Consulting Fee
Servier: Honoraria; Grant/Research Support

NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses no relevant financial relationships:
Ndiya Ogba, PhD (Employed by NCCN until 1/15/21)

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-20-111-L01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

This webinar was presented live one time only on Friday, January 22, 2021, from 2:00 - 3:00 PM EST (UTC -5).

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing